23 Jul, 2026
According to Straits Research, the global pharmerging market size was valued at $1.82 trillion in 2025 and is projected to grow from $1.87 trillion in 2026 to $2.28 trillion by 2034 at a CAGR of 2.5% during the forecast period 2026-2034.
The pharmerging market refers to pharmaceutical markets in rapidly developing economies where healthcare spending is increasing significantly. These countries, typically classified into Tier 1, Tier 2, and Tier 3 based on economic scale, exhibit high pharmaceutical demand due to expanding healthcare infrastructure, rising incomes, and government-led healthcare reforms. The pharmerging market is experiencing rapid expansion, fueled by increasing disease burden, improving healthcare accessibility, and strong policy-driven initiatives.
The rapid expansion of universal healthcare coverage in pharmerging markets is significantly enhancing access to medical services and pharmaceuticals. Governments are implementing policies to extend healthcare services to underserved populations, thereby increasing the demand for medications.
Such initiative exemplifies the global commitment to achieving universal health coverage, further driving the pharmaceutical market growth in emerging economies.
The development of low-cost biosimilars for chronic diseases offers a promising solution to the high cost of biologic therapies in pharmerging markets. Biosimilars provide comparable efficacy to original biologics at a reduced cost, increasing accessibility for patients.
Such initiative aims to broaden access to advanced treatments for conditions such as cancer and autoimmune disorders, addressing the growing demand for affordable healthcare solutions in these regions.
North America holds a leading position in the global pharmerging market due to its strong pharmaceutical R&D ecosystem, high adoption of biologics and biosimilars, and advanced regulatory pathways that accelerate drug approvals. The region benefits from extensive government funding for healthcare initiatives, a well-established biopharmaceutical manufacturing infrastructure, and a robust network of CROs supporting clinical trials.
Moreover, increasing collaborations between pharmaceutical giants and emerging biotech firms drive innovation, while favorable reimbursement policies and expanding patient assistance programs enhance market accessibility, solidifying North America's dominance in the pharmerging landscape.
sales@straitsresearch.com